The association between hidradenitis suppurativa and male and female infertility: A population‐based study

Author(s):  
Dana Tzur Bitan ◽  
Khalaf Kridin ◽  
Emmilia Hodak ◽  
Arnon Cohen ◽  
Shany Sherman

Author(s):  
Yun‐Tzu Liang ◽  
Chih‐Jung Yeh ◽  
Jing‐Yang Huang ◽  
James Cheng‐Chung Wei


Author(s):  
J.M. Cohen ◽  
K. Kridin ◽  
L.M. Perez‐Chada ◽  
J.F. Merola ◽  
A.D. Cohen


2013 ◽  
Vol 133 (1) ◽  
pp. 97-103 ◽  
Author(s):  
Benjamin G. Vazquez ◽  
Ali Alikhan ◽  
Amy L. Weaver ◽  
David A. Wetter ◽  
Mark D. Davis


2020 ◽  
pp. jrheum.201166
Author(s):  
Jessica Widdifield ◽  
Jodi M. Gatley ◽  
Janet E. Pope ◽  
Claire E.H. Barber ◽  
Bindee Kuriya ◽  
...  

Objective To compare differences in clinical activity and remuneration between male and female rheumatologists and to evaluate associations between physician gender and practice sizes and patient volume, accounting for rheumatologists’ age, and calendar year effects. Methods We conducted a population-based study in Ontario, Canada between 2000-2015 identifying all rheumatologists practicing as full-time equivalents (FTE) or above and assessed differences in practice sizes (number of unique patients), practice volumes (number of patient visits), and remuneration (total fee-for-service billings) between male and female rheumatologists. Multivariable linear regression was used to evaluate the effects of gender on practice size and volume separately, accounting for age and year. Results The number of rheumatologists practicing at or above one FTE increased from 89 to 120 from 2000 to 2015, with the percentage of females increasing from 27.0% to 41.7%. Males had larger practice sizes and practice volumes. Remuneration was consistently higher for males (between $46,000-$102,000 annually). Our adjusted analyses estimated that in a given year, males saw a mean of 606 (95% CI 107-1105) more patients than females did, and had 1,059 (95% CI 345- 1773) more patient visits. Among males and females combined, there was a small but statistically significant reduction in mean annual number of patient visits, and middle-aged rheumatologists had greater practice sizes and volumes than their younger/older counterparts. Conclusion On average, female rheumatologists saw fewer patients and had fewer patient visits annually relative to males, resulting in lower earnings. Increasing feminization necessitates workforce planning to ensure that populations’ needs are met.



2020 ◽  
Vol 83 (6) ◽  
pp. AB218
Author(s):  
Maria Schneeweiss ◽  
Sebastian Schneeweiss ◽  
Richard Wyss ◽  
Joseph Merola ◽  
David Rosmarin


2014 ◽  
Vol 170 (4) ◽  
pp. 884-889 ◽  
Author(s):  
G.R. Vinding ◽  
I.M. Miller ◽  
K. Zarchi ◽  
K.S. Ibler ◽  
C. Ellervik ◽  
...  


Author(s):  
H Miao ◽  
HM Verkooijen ◽  
KS Chia ◽  
E Pukkala ◽  
S Larønningen ◽  
...  


Blood ◽  
2014 ◽  
Vol 124 (21) ◽  
pp. 2639-2639
Author(s):  
Jayadev Manikkam Umakanthan ◽  
Dipesh Uprety ◽  
Vineela Kasireddy

Abstract Background: Bortezomib is an antineoplastic agent that acts through protease inhibition. Since, its approval in 2003 by U.S. Food and Drug administration, it has been used religiously for multiple myeloma. There is no current population based study that assesses the survival benefit in multiple myeloma from bortezomib. We conducted a population based study to evaluate the relative survival rates in multiple myeloma patients in pre and post-Bortezomib era in the United States. Methods: We analyzed the Surveillance, Epidemiology, and End Results (SEER) 18 registry database to compare five-year relative survival rates (RS) among multiple myeloma patients. The study arms were categorized by gender (male and female), race (Caucasians and African-Americans) and age (20-59, ≥60 years). The RS were compared between pre-bortezomib era (1991-2002) and post-bortezomib era (2004-2011). The survival rate accompanied standard errors and the statistical significance was defined as p value <0.05. Results: The database comprised of 57,328 patients. The RS have improved significantly during post-bortezomib era in all cohorts under consideration. There was no significant difference in survival rate between male and female and between the African American and Caucasian. However, the relative survival was much better with the young adult (20-59 years) as compared to adult ≥60 years. The table detailing the relative survival is given below. Conclusion: The Primary treatment protocols for Multiple Myeloma have changed dramatically since the approval of Bortezomib in 2003. Other novel agents introduced in the last decade include thalidomide, Lenalidomide and liposomal doxorubicin that are used in conjunction with Bortezomib. Survival trends continue to improve and we believe this modest improvement in survival rate is mainly due to the introduction of Bortezomib and other novel agents. The next challenge is to find new drugs which would prevent relapses and further prolong survival. Abstract 2639. Table.Study armSubclass of cohortsPre-bortezomib era (1991-2002)Post- bortezomib era (2004-2011)Z scoreP ValueNRS (%)Relative Standard Error (SE) (%)NRS (%)Relative Standard Error (SE) (%) GenderMale13,06634.60.517,76546.10.615.904<0.0001Female11,58032.10.514,91743.70.614.765<0.0001 RaceCaucasian18,83632.90.423,98145.00.519.259<0.0001African American4,27434.70.86,39145.10.98.488<0.0001 Age group20-596,35848.10.69,43960.20.712.920<0.0001>=6018,28827.80.423,24338.40.516.606<0.0001 Total: male and female: 1991-2002; 24,646, RS 33.4%; SE 0.3%; 2004-2011; 32,682, RS 45.0%, SE 0.4%; Z score 21.766, P value <0.0001. Disclosures No relevant conflicts of interest to declare.



Author(s):  
Khalaf Kridin ◽  
Payal M. Patel ◽  
Virginia A. Jones ◽  
Giovanni Damiani ◽  
Kyle T. Amber ◽  
...  


Sign in / Sign up

Export Citation Format

Share Document